BACKGROUND: We have previously shown that our patient population of 60% minority races has end-stage renal disease primarily as a result of diabetes mellitus and hypertension. It therefore was logical to explore the restoration of normal insulin production and renal function by simultaneous pancreas-kidney (SPK) transplantation, without regard to race. This study represents new analyses integrating race with C-peptide status and reports the outcome of 136 SPK transplantations performed over the last 10 years. RESULTS: Of the 49 African-Americans with diabetes mellitus and end-stage renal disease, 60% were type I and 40% were type II, based on C-peptide levels. In comparison, only 16% of Caucasians were type II. The average age at onset of diabetes mellitus was 15.7 years for type I compared with 20.7 years for type II (P>0.05). The actuarial 10-year survival rates for the 136 SPKs were 91.79% (patient), 85.07% (pancreas), and 83.58% (kidney). The type I and type II survival rates were similar in the two diabetic groups. CONCLUSIONS: The data strongly suggest that pretransplant C-peptide status does not influence the outcome of SPK transplantation in patients with renal failure from diabetes mellitus. SPK transplants should be offered to all suitable diabetic patients with renal failure regardless of C-peptide status or race.
BACKGROUND: We have previously shown that our patient population of 60% minority races has end-stage renal disease primarily as a result of diabetes mellitus and hypertension. It therefore was logical to explore the restoration of normal insulin production and renal function by simultaneous pancreas-kidney (SPK) transplantation, without regard to race. This study represents new analyses integrating race with C-peptide status and reports the outcome of 136 SPK transplantations performed over the last 10 years. RESULTS: Of the 49 African-Americans with diabetes mellitus and end-stage renal disease, 60% were type I and 40% were type II, based on C-peptide levels. In comparison, only 16% of Caucasians were type II. The average age at onset of diabetes mellitus was 15.7 years for type I compared with 20.7 years for type II (P>0.05). The actuarial 10-year survival rates for the 136 SPKs were 91.79% (patient), 85.07% (pancreas), and 83.58% (kidney). The type I and type II survival rates were similar in the two diabetic groups. CONCLUSIONS: The data strongly suggest that pretransplant C-peptide status does not influence the outcome of SPK transplantation in patients with renal failure from diabetes mellitus. SPK transplants should be offered to all suitable diabeticpatients with renal failure regardless of C-peptide status or race.
Authors: H A Chakkera; J K Bodner; R L Heilman; D C Mulligan; A A Moss; K L Mekeel; M J Mazur; K Hamawi; R M Ray; G L Beck; K S Reddy Journal: Transplant Proc Date: 2010-09 Impact factor: 1.066
Authors: Jeevan Prakash Gopal; Adam McLean; Jeremy Crane; Paul Herbert; Vassilios Papalois; Frank J M F Dor; Anand Rathnasamy Muthusamy Journal: Transpl Int Date: 2022-06-15 Impact factor: 3.842
Authors: Jeffrey Rogers; Colleen L Jay; Alan C Farney; Giuseppe Orlando; Marie L Jacobs; David Harriman; Venkat Gurram; Berjesh Sharda; Komal Gurung; Amber Reeves-Daniel; William Doares; Scott Kaczmorski; Alejandra Mena-Gutierrez; Natalia Sakhovskaya; Michael D Gautreaux; Robert J Stratta Journal: Clin Transplant Date: 2022-01-31 Impact factor: 3.456